Novel class of MCTs for treatment of cognitive health and neurological disorders

Medium chain triglycerides (MCTs) have found use in a number of applications because of their unique physical attributes.  It is well known that consumption of MCTs results in increased production of ketones compared to long chain triglycerides (LCTs).  Ketones are the only alternatives to glucose as an energy source for the brain and can be used to provide the energy needed for normal function.  As such, MCTs have been used to treat neurological disorders and improve cognitive health.  Some applications, such as epilepsy, require relatively high doses of MCTs (15-30 g/day).  This amount of MCT oil can cause gastrointestinal distress and other undesired side effects.  More efficacious MCTs would reduce the dosing needed to get a comparable level of ketones to the brain.  Traditionally, MCTs contain even chain fatty acids with chain lengths of 6 to 12 carbons.  We wish to present findings on MOEFA (Mixed Odd/Even Fatty Acids) MCTs, a novel class of MCTs.  These compounds show improved performance when compared to placebos and currently available MCTs in a number of cognitive health and neurological disorder treatment applications.